18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To evaluate the usefulness of [18F]fluoromisonidazole ([18F]FMISO)-positron emission tomography (PET) prior to the treatment of head and neck squamous cell carcinoma.
Seventeen patients with untreated HNSCC underwent pretreatment [18F]FMISO PET. Six of them underwent definitive surgery and the remaining 11 definitive (chemo-)radiotherapy. We evaluated 30 lesions from the 17 patients. SUVmax and tumor-to-muscle ratios (TMR) were measured as hypoxia indicators. Tumors equal to or above the median value were defined as tumor with high uptake of [18F]FMISO and those below as tumor with low uptake of [18F]FMISO in both indicators. Local control rates with radiotherapy, event-free survival and disease-specific survival (DSS) rates with radiotherapy or operation were compared.
[18F]FMISO-PET imaging of 30 lesions resulted in a SUVmax median value of 2.3 and a TMR median value of 1.3. Local control rates with radiotherapy (20-month median follow-up duration) were significantly lower in the tumor group with high uptake of [18F]FMISO compared to the tumor group with low uptake of [18F]FMISO using either SUVmax or TMR as the hypoxic indicator (P = 0.02 and 0.04, respectively). DSS rate with radiotherapy or operation (21-month median follow-up duration) was significantly lower in the patient group with high uptake of [18F]FMISO compared to the patient group with low uptake of [18F]FMISO defined by SUVmax (P = 0.04), but was not by TMR (P = 0.57).
Radiotherapy outcome and survival prognosis (radiotherapy or operation) in HNSCC may be predicted by carrying out [18F]FMISO PET before treatment.
- Jain, RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29: pp. 3-9
- Piert M. Hypoxia Imaging. In: Wahl RL, editor. Principles and practice of PET and PET/CT. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 464–71.
- Wouters, A, Pauwels, B, Lardon, F, Vermorken, JB (2007) Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 12: pp. 690-712 CrossRef
- Stadler, P, Becker, A, Feldmann, HJ, Hänsgen, G, Dunst, J, Würschmidt, F (1999) Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44: pp. 749-754 CrossRef
- Lartigau, E, Lusinchi, A, Weeger, P, Wibault, P, Luboinski, B, Eschwege, F (1998) Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer 34: pp. 856-861 CrossRef
- Hockel, M, Schlenger, K, Aral, B, Mitze, M, Schaffer, U, Vaupel, P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: pp. 4509-4515
- Nordsmark, M, Alsner, J, Keller, J, Nielsen, OS, Jensen, OM, Horsman, MR (2001) Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 84: pp. 1070-1075 CrossRef
- Clavo, B, Pérez, JL, López, L, Suárez, G, Lloret, M, Morera, J (2003) Influence of haemoglobin concentration and peripheral muscle pO2 on tumour oxygenation in advanced head and neck tumours. Radiother Oncol 66: pp. 71-74 CrossRef
- Chapman, JD (1979) Hypoxic sensitizers—implications for radiation therapy. N Engl J Med 301: pp. 1429-1432 CrossRef
- Jerabek, PA, Patrick, TB, Kilbourn, MR, Dischino, DD, Welch, MJ (1986) Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum A 37: pp. 599-605 CrossRef
- Grierson, JR, Link, JM, Mathis, CA, Rasey, JS, Krohn, KA (1989) A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 30: pp. 343-350
- Yamane, T, Kikuchi, M, Shinohara, S, Senda, M (2011) Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol 13: pp. 227-231 CrossRef
- Kikuchi, M, Shinohara, S, Nakamoto, Y, Usami, Y, Fujiwara, K, Adachi, T (2011) Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma. Mol Imaging Biol 13: pp. 368-377 CrossRef
- Tang, G, Wang, M, Tang, X, Gan, M, Luo, L (2005) Fully automated one-pot synthesis of [18F]fluoromisonidazole. Nucl Med Biol 32: pp. 553-558 CrossRef
- Oh, SJ, Chi, DY, Mosdzianowski, C, Kim, JY, Gil, HS, Kang, SH (2005) Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module. Nucl Med Biol 32: pp. 899-905 CrossRef
- Eschmann, SM, Paulsen, F, Reimold, M, Dittmann, H, Welz, S, Reischl, G (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 46: pp. 253-260
- Gray, LH, Conger, AD, Ebert, M, Hornsey, S, Scott, OC (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: pp. 638-648 CrossRef
- Brown, JM (1999) The hypoxic cell: a target for selective cancer therapy–eighteenth Bruce F Cain Memorial Award lecture. Cancer Res 59: pp. 5863-5870
- Horan, AD, Koch, CJ (2001) The Km for radiosensitization of human tumor cells by oxygen is much greater than 3 mmHg and is further increased by elevated levels of cysteine. Radiat Res 156: pp. 388-398 CrossRef
- Rasey, JS, Grunbaum, Z, Magee, S, Nelson, NJ, Olive, PL, Durand, RE (1987) Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 111: pp. 292-304 CrossRef
- Rasey, JS, Nelson, NJ, Chin, L, Evans, ML, Grunbaum, Z (1990) Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 122: pp. 301-308 CrossRef
- Rasey, JS, Koh, WJ, Evans, ML, Peterson, LM, Lewellen, TK, Graham, MM (1996) Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36: pp. 417-428 CrossRef
- Nordsmark, M, Overgaard, M, Overgaard, J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: pp. 31-39
- Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 2007;7:113.
- Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51.
- Tatum, JL, Kelloff, GJ, Gillies, RJ, Arbeit, JM, Brown, JM, Chao, KS (2006) Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82: pp. 699-757 CrossRef
- Kubota, K, Tada, M, Yamada, S, Hori, K, Saito, S, Iwata, R (1999) Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 26: pp. 750-757 CrossRef
- Spence, AM, Muzi, M, Swanson, KR, O’Sullivan, F, Rockhill, JK, Rajendran, JG (2008) Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14: pp. 2623-2630 CrossRef
- Rajendran, JG, Schwartz, DL, O’Sullivan, J, Peterson, LM, Ng, P, Scharnhorst, J (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12: pp. 5435-5441 CrossRef
- Thorwarth, D, Eschmann, SM, Paulsen, F, Alber, M (2005) A kinetic model for dynamic [18F]-FMISO PET data to analyse tumour hypoxia. Phys Med Biol 50: pp. 2209-2224 CrossRef
- 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma
Annals of Nuclear Medicine
Volume 25, Issue 9 , pp 625-633
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- [18F]fluoromisonidazole ([18F]FMISO)
- Positron emission tomography (PET)
- Head and neck cancer
- Prediction of prognosis
- Industry Sectors
- Author Affiliations
- 1. Department of Otolaryngology, Head and Neck Surgery, Kobe City Medical Center General Hospital, 4-6 Minatojima-Nakamachi, Chuo-ku, Kobe, 650-0046, Japan
- 2. Division of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan
- 3. Department of Otolaryngology, Shizuoka General Hospital, Shizuoka, Japan